Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of PF-07202954 in Healthy Adults
NCT04857437Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07202954 in non-alcoholic fatty liver disease (NAFLD) and Liver Fibrosis (LF) (5 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to 6 weeks, Number of Participants With Laboratory Abnormalities Meeting Pre-defined Criteria up to 6 weeks and 6 more. Started May 2021; status: completed.
02
Drugs
PF-07202954
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT04857437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857437.